Tres Alchemix Co.Ltd.

Tres Alchemix is an AI-native biotechnology company developing a predictive drug-design platform to create next-generation small-molecule therapies. By integrating multi-omic and multimodal datasets with proprietary quantum-chemical calculation methods, it is building a human in silico model capable of forecasting the efficacy and safety of novel compounds. Founded in 2023 in Fukuoka, Japan, Tres Alchemix is expanding its operations in the United Kingdom with a new laboratory at The Oxford Science Park.